Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Inflammation Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of a Facemask Device to Treat Hypotension

NCT00256724
View directory record Official record
Conditions
Hypotension
Interventions
Impedance Threshold Device, sham ITD
Device
Lead sponsor
Advanced Circulatory Systems
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Not applicable Interventional

Study to Determine Therapeutic Massage Dosing to Improve Quality of Life in Hospitalized Patients Receiving Palliative Care

NCT04916223
View directory record Official record
Conditions
Cancer, Heart Failure, COPD, Sepsis, HIV Infections, ESRD, Trauma, Stroke
Interventions
Therapeutic massage
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

NCT01598831
View directory record Official record
Conditions
Severe Sepsis, Coagulopathy
Interventions
ART-123, Placebo
Drug
Lead sponsor
Asahi Kasei Pharma America Corporation
Industry
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 23, 2026, 6:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

NCT00958815
View directory record Official record
Conditions
Insulin Resistance, Atherosclerosis, Cardiovascular Disease, HIV/AIDS, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
35 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

NCT00362908
View directory record Official record
Conditions
Metabolic Syndrome X, Dyslipidemias
Interventions
Moderate Fat and Moderate Carbohydrate Diet, Low Fat and High Carbohydrate Diet
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 23, 2026, 6:51 PM EDT
Not listed No phase listed Observational

Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage

NCT03604276
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Headache, Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
60 participants
Timeline
2017 – 2026
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 23, 2026, 6:51 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

NCT06854640
View directory record Official record
Conditions
Sepsis, Coagulopathy
Interventions
BAY3389934
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Not applicable Interventional

Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair

NCT03208920
View directory record Official record
Conditions
PAD, Abdominal Aortic Aneurysm
Interventions
Pro-Omega, ProOmega Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT00366249
View directory record Official record
Conditions
Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions
Tigecycline, Ertapenem
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Los Angeles, California • Northridge, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 23, 2026, 6:51 PM EDT
Completed No phase listed Observational

Dysregulated CNS Inflammation After Acute Brain Injury

NCT03287557
View directory record Official record
Conditions
Traumatic Brain Injury, Aneurysmal Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 101 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 23, 2026, 6:51 PM EDT
Completed No phase listed Observational

Vascular Inflammation in Adolescents With Type 1 Diabetes

NCT00933101
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Not applicable Interventional

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

NCT01769963
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Research diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 23, 2026, 6:51 PM EDT
Enrolling by invitation Not applicable Interventional

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

NCT07499128
View directory record Official record
Conditions
Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions
TempTraq, VitalTraq
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Recruiting Not applicable Interventional

Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke

NCT07404852
View directory record Official record
Conditions
Large Vessel Occlusion, Acute Ischemic Stroke
Interventions
transcutaneous auricular vagal nerve stimulation, Sham transcutaneous vagal nerve stimulation
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

NCT00570752
View directory record Official record
Conditions
Vascular Diseases
Interventions
Placebo, BMS-582949, Atorvastatin, Statin
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

NCT00312052
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Alpena, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease

NCT00014040
View directory record Official record
Conditions
Coronary Disease, Myocardial Ischemia
Interventions
Nitric Oxide and INOpulse Delivery System
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

NCT00071227
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion
Interventions
Triamcinolone Acetonide (TAC-PF)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Not applicable Interventional

Improving Safety of Diagnosis and Therapy in the Inpatient Setting

NCT04393909
View directory record Official record
Conditions
Delirium, Confusion, Mental Status Change, Back Pain, Hip Pain Chronic, Chest Pain, Asthma, COPD, Cellulitis, Soft Tissue Infections, Cough, Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism, Dyspnea, Electrolyte Metabolism Abnormal, Fever, Failure to Thrive, Weakness, Protein-Calorie Malnutrition, Headache, Neck Pain, Hypoxia, Pneumonia, Sepsis, Syncope, Vomiting, Diarrhea, Leg Pain, Abdominal Pain
Interventions
Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire, Enhancements to Epic-integrated Quality & Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 4 Interventional Results available

Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

NCT01663103
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 23, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629
View directory record Official record
Conditions
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
30 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 6:51 PM EDT